Natera, Inc. ($NTRA) Stock Forecast: Up 5.5% Today

What is Natera, Inc.?

A company specializing in cell-free DNA and genetic testing for oncology, women's health, and organ health, Natera, Inc. (NASDAQ: NTRA) witnessed a strong bullish movement today.

Why is Natera, Inc. going up?

NTRA stock is up 5.5% on Feb 18, 2026 15:16

• Anticipation and positive sentiment among investors were fueled by Natera's announcement of the upcoming release of its fourth quarter and full-year results.
• Institutional investors, such as Zweig DiMenna Associates LLC, increased their stake, indicating confidence in Natera's future performance and contributing to the bullish trend.
• Despite some company insiders selling off shares, the market remains optimistic about Natera's growth potential, evident from the stock's positive movement.
• An average price target of $249.20 alongside analysts' "Moderate Buy" consensus rating bode well for Natera, reinforcing the bullish market sentiment.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth quarter and full-year results for 2025 on February 26, 2026, after the market closes. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss these financial results. Natera specializes in cell-free DNA and genetic testing for oncology, women’s health, and organ health.

https://ca.finance.yahoo.com/news/natera-report-fourth-quarter-full-140000267.html

Zweig DiMenna Associates LLC Buys 8,400 Shares of Natera, Inc. $NTRA

Zweig DiMenna Associates LLC has increased its stake in Natera, Inc. by 6.8%, acquiring an additional 8,400 shares and bringing its total holdings to 132,500 shares, valued at approximately $21.33 million. This makes Natera the firm's 15th largest holding, representing about 1.5% of its portfolio. While institutional investors are increasing positions, company insiders have been net sellers, offloading 455,899 shares worth over $106 million in the last 90 days.

https://www.marketbeat.com/instant-alerts/filing-zweig-dimenna-associates-llc-buys-8400-shares-of-natera-inc-ntra-2026-02-17/

Natera, Inc. (NTRA) reports preliminary Q4 revenue

Natera, Inc. (NTRA) has released its preliminary revenue figures for the fourth quarter. The company has a market capitalization of $11.53 billion and an average trading volume of 1.13 million shares. This announcement provides an early look at their financial performance.

http://www.msn.com/en-us/health/other/natera-inc-ntra-reports-preliminary-q4-revenue/ar-AA1VfrkV?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

How (NTRA) Movements Inform Risk Allocation Models

This article analyzes Natera Inc. (NASDAQ: NTRA) focusing on its stock movements to inform risk allocation models. It highlights a positive near-term sentiment within a long-term strong context, despite a mid-term weak bias, and details three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss points. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.

https://news.stocktradersdaily.com/news_release/39/How_NTRA_Movements_Inform_Risk_Allocation_Models_021526094002_1771166402.html

Envestnet Asset Management Inc. Purchases 17,254 Shares of Natera, Inc. $NTRA

Envestnet Asset Management Inc. increased its stake in Natera, Inc. by 10% in the third quarter, acquiring an additional 17,254 shares to own a total of 189,276 shares valued at approximately $30.47 million. Despite this, company insiders have been net sellers, with the CFO selling shares and total insider sales reaching roughly $106.48 million in the last three months. Wall Street analysts maintain a "Moderate Buy" consensus rating for Natera with an average price target of $249.20.

https://www.marketbeat.com/instant-alerts/filing-envestnet-asset-management-inc-purchases-17254-shares-of-natera-inc-ntra-2026-02-12/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.0% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 10.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 5.6% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 8.6% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Up 5.1% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Down 5.5% Today

Fifth Third Bancorp ($FITB) Stock Forecast: Down 5.5% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Down 8.2% Today

International Business Machines Corporation ($IBM) Stock Forecast: Down 12.4% Today

Accenture plc Class A (Ireland) ($ACN) Stock Forecast: Down 5.6% Today

Natera, Inc. Price History

04.01.2026 - NTRA Stock was down 8.9%

• The decrease in Natera Inc. (NTRA) stock value may be due to a combination of strong revenue performance but a miss in earnings per share, as well as recent insider selling.
• Concerns around regulatory approval timelines and market potential arose following the FDA premarket approval application for Natera's Signatera CDx test in muscle-invasive bladder cancer (MIBC).
• Despite analyst optimism with a "Moderate Buy" rating and a high target price, the surge in institutional ownership and insider selling likely led to short-term selling pressure, contributing to the bearish market trend.

04.01.2026 - NTRA Stock was down 7.7%

• The decline in Natera's stock today may be influenced by various factors:
• Positive developments, such as the FDA PMA application for the Signatera CDx test for bladder cancer, were overshadowed by concerns related to the company's financial performance. Natera fell short on EPS, and significant insider selling took place, amounting to over $114 million in the previous quarter.
• The substantial insider selling likely created selling pressure on the stock in the short term.
• Despite increased stakes by institutional investors like the New York State Common Retirement Fund and Mirae Asset Global Investments Co. Ltd., the notable insider selling and earnings miss could have affected overall investor sentiment.
• While the decrease in short interest in January suggested a decline in bearish sentiment, today's market movement implies that other factors impacted the stock more significantly.

08.00.2026 - NTRA Stock was down 5.4%

• Despite recently reaching an all-time high, Natera Inc. (NTRA) experienced a bearish market movement today, possibly due to concerns raised about the stock's valuation compared to its Fair Value.
• The company's financial outlook, supported by positive developments such as the expanded Fetal Focus test and ALTAIR trial results, still harbors uncertainties regarding further reimbursement and guideline wins to counterbalance high expenses.
• The bearish movement may also be influenced by projections of negative net income for the year, despite increased price targets from various firms.
• Investors may be exercising caution regarding the stock's valuation and the company's capacity to convert clinical progress into sustainable financial growth, contributing to the observed bearish market movement today.

06.00.2026 - NTRA Stock was up 6.3%

• The positive outcomes presented at the ASCO GI Symposium from its ALTAIR trial, showcasing significant disease-free survival benefits for colorectal cancer patients, likely contributed to Natera's bullish movement.
• Natera's stock price target was increased to $270 by Guggenheim, along with other analysts' optimistic adjustments, fueling investor confidence.
• The launch of the expanded 21-gene Fetal Focus single-gene non-invasive prenatal test further demonstrates Natera's commitment to innovation and product expansion, attracting more attention from investors.
• Strong revenue growth and positive market sentiment have driven the stock price upwards, overshadowing concerns such as insider selling and reduced stake by Calamos Advisors LLC.

12.00.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock price today could be attributed to several factors:
• Despite Natera's strong preliminary fourth-quarter revenue and positive news surrounding its oncology tests, the market may have reacted negatively to President Moshkevich's significant stock sale, which could have raised concerns among investors.
• The collaboration with Exelixis on the STELLAR-316 trial for colorectal cancer patients, while promising in the long term, might have created uncertainty in the short term due to the expected initiation of the trial in mid-2026.
• The lack of specific details in the findings from the CALGB (Alliance)/SWOG 80702 study could have left investors wanting more clarity on the potential impact of the study results on Natera's products and services.
• Overall market conditions or sector-specific trends may have also played a role in the bearish movement of Natera's stock today, despite the positive developments highlighted in recent news.

22.00.2026 - NTRA Stock was up 5.1%

• Acquisition of a new position in Natera by Rakuten Investment Management Inc. reflects confidence in the company's future.
• Study results for Natera's colorectal cancer detection assay have been promising, showcasing the company's innovative technology and growth potential.
• Natera's publication of clinical validation for its tfMRD test in colorectal cancer reinforces its position as a leader in precision oncology.
• Selection of Natera's Fetal Focus sgNIPT for a prestigious presentation at the SMFM meeting underlines the company's advancements in genetic screening, likely contributing to positive market sentiment.

06.01.2026 - NTRA Stock was down 6.2%

• Natera's President and Chief Business Officer selling a substantial amount of company stock to cover tax obligations might have signaled a lack of confidence in the company's short-term performance, contributing to the bearish movement.
• The sale of Natera stock by the President of Clinical Diagnostics, following a period of stock volatility and concerns about overvaluation, could have added to the negative sentiment among investors.
• The mid-day trading price drop of 7.82% on February 4th could be a result of a combination of insider selling, perceived overvaluation, and overall market volatility affecting Natera's stock price.
• The AI-driven trading systems highlighting weak near-term sentiment despite long-term strength might have influenced traders to react to the short-term risks associated with Natera, leading to the bearish movement in the stock price.

16.09.2025 - NTRA Stock was up 5.2%

• Natera has demonstrated impressive performance over the last 5 years, surpassing market performance by 5.63% annually, likely attracting investors seeking high returns.
• The company's emphasis on cutting-edge genetic testing technologies and its market capitalization of $23.35 billion have bolstered investor confidence and a positive market outlook.
• The favorable sentiment surrounding Natera's historical performance and growth prospects could have triggered heightened buying activity, resulting in today's notable bullish movement in the stock.

05.01.2026 - NTRA Stock was down 5.5%

• The bearish market movement of NTRA stock could be linked to insider selling activities by the company's top executives, such as President Moshkevich and President Fesko, leading to concerns among investors about the company's future prospects.
• Despite strong preliminary Q4 2025 results and advancements in diagnostic technologies, the stock saw a notable decline possibly because of profit-taking by insiders and investor reactions to perceived stock overvaluation.
• The submission of Signatera CDx PMA to the FDA for detecting molecular residual disease in bladder cancer patients could act as a positive long-term catalyst for Natera. However, short-term market sentiment appears influenced more by insider selling and valuation concerns.
• AI-driven trading systems highlighting weak near-term sentiment and a significant risk-reward setup targeting an 11.5% gain might have also contributed to increased volatility and downward pressure on NTRA stock.

11.11.2025 - NTRA Stock was down 3.8%

• Insider selling, specifically by company directors and the CEO, could be a reason behind Natera's stock downturn, despite recent positive developments like the acquisition of Foresight Diagnostics and strong Q3 results.
• The acquisition of Foresight Diagnostics for up to $450 million may have raised investor concerns about integration challenges and potential value dilution.
• While institutional investors have significantly increased their positions and analysts have given positive ratings, ongoing insider selling, especially by top management, has created uncertainty and possibly triggered stock sell-offs.
• Despite optimistic analyst outlooks and robust revenue performance, continuous insider selling activities, including by key executives, might have unsettled investors and contributed to the bearish trend in Natera's stock today.

07.10.2025 - NTRA Stock was down 5.0%

• Natera exceeded revenue predictions but faced a notable loss in Q3 earnings, potentially influencing the stock's downturn.
• Worries about Natera's profitability outlook may have prompted investors to sell off the company's shares.
• The combination of uneven performance and a significant earnings shortfall could have eroded investor faith in Natera's future growth, triggering adverse market movements.

18.01.2026 - NTRA Stock was up 5.5%

• Anticipation and positive sentiment among investors were fueled by Natera's announcement of the upcoming release of its fourth quarter and full-year results.
• Institutional investors, such as Zweig DiMenna Associates LLC, increased their stake, indicating confidence in Natera's future performance and contributing to the bullish trend.
• Despite some company insiders selling off shares, the market remains optimistic about Natera's growth potential, evident from the stock's positive movement.
• An average price target of $249.20 alongside analysts' "Moderate Buy" consensus rating bode well for Natera, reinforcing the bullish market sentiment.